| abstract |
The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The variant comprises at least one amino acid substitution in one of the positions S132 and S142, and at least one amino acid substitution in one of the positions R137, R139 and R140. Alternatively, the variant comprises at least amino acid substitutions in positions R137 and R140. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. |